ConductScience.org, home

Paper42266751

Schisandrin A suppresses hepatocellular carcinoma and sensitizes to sorafenib via modulating retinol metabolism.

Zhou Y and 6 others. Am J Cancer Res, 2026. Cited by 0 papers, by iCite.

Cite this record

ConductScience Library. Schisandrin A suppresses hepatocellular carcinoma and sensitizes to sorafenib via modulating retinol metabolism. Papers, record 42266751. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42266751

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Schisandrin A suppresses hepatocellular carcinoma and sensitizes to sorafenib via modulating retinol metabolism.
PubMed
Journal
Am J Cancer Res
PubMed
Year
2026
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
0
iCite
Revised in PubMed
2026-08-13
PubMed

Authors7

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Zhou YYu
2Mao YYufan
3Fu XXueliang
4Li YYanan
5Xu MMeng
6Zhou DDeliang
7Zha SShuai

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References31

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
139838407Tailoring traditional Chinese medicine in cancer therapy.Mol Cancer2025https://conductscience.org/library/papers/39838407PubMed
234256124Treatment for liver cancer: From sorafenib to natural products.Eur J Med Chem2021https://conductscience.org/library/papers/34256124PubMed
334643254Schizandrin A can inhibit non‑small cell lung cancer cell proliferation by inducing cell cycle arrest, apoptosis and autophagy.Int J Mol Med2021https://conductscience.org/library/papers/34643254PubMed
432889778Icaritin-induced immunomodulatory efficacy in advanced hepatitis B virus-related hepatocellular carcinoma: Immunodynamic biomarkers and overall survival.Cancer Sci2020https://conductscience.org/library/papers/32889778PubMed
540490812Natural anti-cancer products: insights from herbal medicine.Chin Med2025https://conductscience.org/library/papers/40490812PubMed
639599215Magnetic Molecularly Imprinted Polymer Combined with Solid-Phase Extraction for Purification of Schisandra chinensis Lignans.Polymers (Basel)2024https://conductscience.org/library/papers/39599215PubMed
737910285Schisandrin A Alleviates Spatial Learning and Memory Impairment in Diabetic Rats by Inhibiting Inflammatory Response and Through Modulation of the PI3K/AKT Pathway.Mol Neurobiol2024https://conductscience.org/library/papers/37910285PubMed
840424981Icaritin induces paraptosis in hepatocellular carcinoma cells by targeting BHLHE40 via endoplasmic reticulum stress and mitochondrial dysfunction.Phytomedicine2025https://conductscience.org/library/papers/40424981PubMed
938382281Schisandrin A alleviates renal fibrosis by inhibiting PKCβ and oxidative stress.Phytomedicine2024https://conductscience.org/library/papers/38382281PubMed
1039354529Traditional Chinese medicine for the treatment of cancers of hepatobiliary system: from clinical evidence to drug discovery.Mol Cancer2024https://conductscience.org/library/papers/39354529PubMed
1140513323Efficacy and safety of Chinese medicine in treating risk window of AECOPD: A multicenter randomized controlled trial.Phytomedicine2025https://conductscience.org/library/papers/40513323PubMed
1218650514Sorafenib in advanced hepatocellular carcinoma.N Engl J Med2008https://conductscience.org/library/papers/18650514PubMed
1339949800Material basis revelation of anti-hepatoma effect of Huachansu (Cinobufacini) through down-regulation of thymidylate synthase.Chin Herb Med2025https://conductscience.org/library/papers/39949800PubMed
1432110802Schizandrin A exhibits potent anticancer activity in colorectal cancer cells by inhibiting heat shock factor 1.Biosci Rep2020https://conductscience.org/library/papers/32110802PubMed
1536604718Targeting fatty acid synthase modulates sensitivity of hepatocellular carcinoma to sorafenib via ferroptosis.J Exp Clin Cancer Res2023https://conductscience.org/library/papers/36604718PubMed
1636175804The natural medicinal fungus Huaier promotes the anti-hepatoma efficacy of sorafenib through the mammalian target of rapamycin-mediated autophagic cell death.Med Oncol2022https://conductscience.org/library/papers/36175804PubMed
1740392748Advances in the treatment of hepatocellular carcinoma: An overview of the current and evolving therapeutic landscape for clinicians.CA Cancer J Clin2025https://conductscience.org/library/papers/40392748PubMed
1838552434Lignan contents of Schisandra chinensis (Turcz.) Baill. from different origins-A new model for evaluating the content of prominent components of Chinese herbs.Phytomedicine2024https://conductscience.org/library/papers/38552434PubMed
1940475000Donafenib and sintilimab combined with hepatic arterial infusion chemotherapy for unresectable hepatocellular carcinoma: a prospective, single-arm phase II trial (DoHAICs study).EClinicalMedicine2025https://conductscience.org/library/papers/40475000PubMed
2035345394The Research Progress of Bufalin in the Treatment of Hepatocellular Carcinoma.Onco Targets Ther2022https://conductscience.org/library/papers/35345394PubMed

See all 31 referencesDownload CSV of references

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Cited by
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/42266751

GET https://conductscience.org/api/papers/v1/42266751/references?page=2